{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["advanced/recurrent colon cancer or rectal cancer"],"disease":["Advanced/recurrent Colon Cancer Or Rectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2616222"],"location":["Japan"],"study_start_month":["8"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase II study of using Carbamazepine for neurosensory toxicity related FOLFOX regimens in patients with advanced/recurrent colorectal cancer (OGSG 0603)","description":"Interventions: Carbamazepin is administered during FOLFOX therapy. Carbamazepin tablet 100mg, 200mg or granule including Car. 500mg in 1000mg\nPrimary outcome(s): To test the feasibility of Carmazepin therapy and to evaluate whether Carmazepin has the protective and/or prophylactic effects against peripheral nerve syndrome due to FOLFOX therapy\nStudy Design: Single arm Non-randomized","dates":{"creation":"2006-08-15"},"accession":"2616222","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000000718"]}}